Wealthfront Advisers
RVMD icon

Wealthfront Advisers’s Revolution Medicines RVMD Stock Holding History

Wealthfront Advisers’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$320K Buy
+1,710
New +$250K ﹤0.01% 970

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Wealthfront Advisers's RVMD Position: Q2 2026 in Review

Wealthfront Advisers opened a new position in Revolution Medicines (RVMD) in Q2 2026: 1,710 shares worth $320K. The stake represents ﹤0.01% of the portfolio and ranks #970 among its holdings.

689 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Wealthfront Advisers held 1,710 shares of Revolution Medicines worth $320K as of Q2 2026.
  • Revolution Medicines was a new Wealthfront Advisers position in Q2 2026.
  • Revolution Medicines made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #970 holding.
  • 689 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.